JBIO SCHEDULE 13G/A: SEC filing

Bellevue Group AG and its subsidiary Bellevue Asset Management AG

Filed with the SEC on · accession 0001104659-26-128591

JBIO filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. A report the company filed with the SEC (the US market regulator). The stock moved -5.0% by the first close after the filing.

Summary of the filing

Bellevue Group AG and its subsidiary Bellevue Asset Management AG filed an amended Schedule 13G reporting beneficial ownership of 4,293,937 shares, or 6.8%, of Jade Biosciences, Inc. common stock as of September 30, 2026.

Key details

shares beneficially owned$4.3M
percent of class beneficially ownedPCT 7
shares outstanding$63.6M
Filer / beneficial ownerBellevue Group AG
Wholly-owned subsidiary of filer / beneficial ownerBellevue Asset Management AG
IssuerJade Biosciences, Inc.
Chief financial officer, bellevue group agStefano Montalbano
Head legal & compliance, bellevue group ag / bellevue asset management agChristoph Eisenring
Chief finance & controlling, bellevue asset management agIvo Betschart

How JBIO stock reacted

Close before

$16.14

Nov 13, 2026

First close after

-4.99%

$15.34

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for JBIO, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for JBIO?

Click here

Frequently asked questions

What did JBIO file with the SEC on Nov 16, 2026?

JBIO filed a SCHEDULE 13G/A (SEC filing). Bellevue Group AG and its subsidiary Bellevue Asset Management AG filed an amended Schedule 13G reporting beneficial ownership of 4,293,937 shares, or 6.8%, of Jade Biosciences, Inc. common stock as of September 30, 2026.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did JBIO stock react to this filing?

JBIO closed at $16.14 before the filing and $15.34 on Nov 16, 2026 (-4.99%).

Other JBIO SEC filings

Get alerts when JBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days